PSTV — Plus Therapeutics Share Price
0.000.00%
Last trade - 00:00- $11.01m
- $10.70m
- $5.82m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.89 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -252.32% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.3 | n/a | 0.22 | 4.91 | 5.82 | 6.47 | 7.04 | -3.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Directors
- Richard Hawkins NEC (72)
- Marc Hedrick PRE
- Andrew Sims CFO (48)
- Norman LaFrance OTH (72)
- Howard Clowes IND (67)
- Robert Lenk IND (73)
- Greg Petersen IND (58)
- Annigje Van Es-johansson IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 16th, 1997
- Public Since
- August 9th, 2000
- No. of Shareholders
- 17
- No. of Employees
- 21
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 16,999,626
- Address
- 4200 Marathon Blvd., Suite 200, AUSTIN, 78756
- Web
- http://www.plustherapeutics.com/
- Phone
- +1 8584580900
- Auditors
- BDO USA, LLP
Upcoming Events for PSTV
Q2 2025 Plus Therapeutics Inc Earnings Release
Q2 2025 Plus Therapeutics Inc Earnings Release
Plus Therapeutics Inc Annual Shareholders Meeting
Similar to PSTV
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Plus Therapeutics share price?
As of Today at 22:41 UTC, shares in Plus Therapeutics are trading at $0.65. This share price information is delayed by 15 minutes.
How has the Plus Therapeutics share price performed this year?
Shares in Plus Therapeutics last closed at $0.65 and the price had moved by -64.01% over the past 365 days. In terms of relative price strength the Plus Therapeutics share price has underperformed the S&P500 Index by -67.54% over the past year.
What are the analyst and broker recommendations for Plus Therapeutics?
The overall consensus recommendation for Plus Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Plus Therapeutics dividend yield?
Plus Therapeutics does not currently pay a dividend.
Does Plus Therapeutics pay a dividend?
Plus Therapeutics does not currently pay a dividend.
When does Plus Therapeutics next pay dividends?
Plus Therapeutics does not currently pay a dividend.
How do I buy Plus Therapeutics shares?
To buy shares in Plus Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Plus Therapeutics?
As of the previous close price of $0.65, shares in Plus Therapeutics had a market capitalisation of $11.01m.
Where are Plus Therapeutics shares listed?
Here are the trading details for Plus Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PSTV
What kind of share is Plus Therapeutics?
Based on an overall assessment of its quality, value and momentum Plus Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Plus Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Plus Therapeutics is $9.63. That is 1386.34% above the last closing price of $0.65.
Analysts covering Plus Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.85 for the next financial year.
Find out moreWhat is the trend in the Plus Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Plus Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -51.79%.
As of the last closing price of $0.65, shares in Plus Therapeutics were trading -48.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Plus Therapeutics PE Ratio?
The Plus Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Plus Therapeutics?
Plus Therapeutics' management team is headed by:
- Richard Hawkins - NEC
- Marc Hedrick - PRE
- Andrew Sims - CFO
- Norman LaFrance - OTH
- Howard Clowes - IND
- Robert Lenk - IND
- Greg Petersen - IND
- Annigje Van Es-johansson - IND